| Literature DB >> 11710583 |
M Saras-Nacenta1, Y López-Púa, L F Lípez-Cortés, J Mallolas, J M Gatell, X Carné.
Abstract
Efavirenz is a non-nucleoside reverse transcriptase inhibitor for the treatment of the HIV infection. A simple, high-performance liquid chromatographic method has been developed and validated for the quantitative determination of efavirenz in human plasma. The method involved solid-phase extraction of the drug and the internal standard (L-737,354) from 300 microl of human plasma. The analysis was via UV detection at 250 nm using a reversed-phase C8 analytical column and a isocratic mobile phase consisting of phosphate buffer (pH 5.75)-acetonitrile that resolved the drug and internal standard from endogenous matrix components and potential coadministered drugs. Within- and between-day precisions were less than 8.6% for all quality control samples. The lower limit of quantification was 0.1 microg/ml. Recovery of efavirenz from human plasma was greater than 83%. This validated assay is being used in pharmacokinetic studies with efavirenz.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11710583 DOI： 10.1016/s0378-4347(01)00357-7
Source DB: PubMed Journal: J Chromatogr B Biomed Sci Appl ISSN： 1387-2273